GLO1 levels and activity can be altered in disease states, including diabetes, cardiomyopathy, and endothelial dysfunction (Jack et al., 2012; Skapare et al., 2013; Hanssen et al., 2014; Yumnam et al., 2020). Here, GLO1 is linked to cardiomyopathy.